請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4044
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林文澧 | |
dc.contributor.author | Yung-Chu Chen | en |
dc.contributor.author | 陳永竹 | zh_TW |
dc.date.accessioned | 2021-05-13T08:41:06Z | - |
dc.date.available | 2020-02-08 | |
dc.date.available | 2021-05-13T08:41:06Z | - |
dc.date.copyright | 2017-02-08 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-10-01 | |
dc.identifier.citation | References
[1] Shoichet MS, Winn SR. Cell delivery to the central nervous system. Adv Drug Deliv Rev 2000;42:81–102. [2] Ngwuluka N, Pillay V, Du Toit LC. Levodopa delivery systems: Advancements in delivery of the gold standard. Expert Opin Drug Deliv 2010;7:203–224. [3] Pathan SA, Iqbal Z, and Zaidi SM. CNS drug delivery systems: Novel approaches. Recent Pat Drug Deliv Formul 2009;3:71–89. [4] Ricci M, Blasi P, Giovagnoli S, and Rossi C. Delivering drugs to the central nervous system: A medicinal chemistry or a pharmaceutical technology issue? Curr Med Chem 2006;13:1757–1775. [5] Patel MM, Goyal BR, Bhadada SV, Bhatt JS. Getting into the brain: Approaches to enhance brain drug delivery. CNS Drugs 2009;23: 35–58. [6] Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007;12:54–61. [7] Merkus P, Guchelaar HJ, Bosch DA, and Merkus FW. Direct access of drugs to the human brain after intranasal drug administration? Neurology 2003;60:1669–1671. [8] Chen Y, Dalwadi G, and Benson HA. Drug delivery across the blood-brain barrier. Curr Drug Deliv 2004;1:361–76. [9] Pardridge WM. William Pardridge discusses the lack of BBB research. Interview by Rebecca N. Lawrence. Drug Discov Today 2002;7:223–226. [10] Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004;104(1):29-45. [11] Banks WA, Kastin AJ. Passage of peptides across the blood-brain barrier: pathophysiological perspectives. Life Sci 1996;59(23):1923-1943. [12] Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003;3(2):90-105. [13] Jong A, Huang SH. Blood-brain barrier drug discovery for central nervous system infections. Curr Drug Targets Infect Disord 2005;5(1):65-72. [14] Kroll RA, Neuwelt EA. Outwitting the blood–brain barrier for therapeuticpurposes: osmotic opening and other means. Congr Neurol Sur 1998;42: 1083–1099. [15] Doolittle ND, Miner ME, Hall WA, Siegal Hanson EJ, Osztie E, McAllister LD, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood–brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000;88:637–647. [16] Fortin D, Gendron C, Boudrias M, Garant MP. Enhanced chemotherapy delivery by intraarterial infusion and blood–brain barrier disruption in the treatment of cerebral metastasis. Cancer 2007;109:751–760. [17] Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Targeted delivery of antibodies through the blood–brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun2006; 340:1085–1090. [18] Borlongan CV, Emerich DF. Facilitation of drug entry into the CNS via transient permeation of blood–brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res Bull 2003;60: 2970306. [19] Dean RL, Emerich DF, Hasler BP, Bartus RT. Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone. Neuro Oncol 1999;1:268–274. [20] Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004;104(1):29-45. [21] Banks WA, Kastin AJ. Passage of peptides across the blood-brain barrier: pathophysiological perspectives. Life Sci 1996;59(23):1923-1943. [22] Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004;25(8):423-429. [23] Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2(1):3-14. [24] Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007;12(1-2): 54-61. [25] Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Thel 2004;104(1):29-45. [26] Liu X, Chen C. Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Disc 2005;8(4):505-512. [27] Béduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 2007;28(33):4947-4967. [28] Visser CC, Voorwinden H, Crommelin DJA, Danhof M, Boer AG. Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm Res 2004;21(5):761-769. [29] Pardridge WM. Tyrosine hydroxylase replacement in experimental Parkinson’s disease with transvascular gene therapy. NeuroRx 2005;2(1):129-138. [30] Li J, Feng L, Fan L, Zha Y, Guo L, Zhang Q, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011;32(21):4943-4950. [31] Yang FY, Wong TT, Teng MC, Liu RS, Lu M, Liang HF, et al. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor in glioblastoma. J Control Release 2012;160(3):652-658. [32] Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005;85(2):495-522. [33] Peeters TL. Ghrelin: a new player in the control of gastrointestinal functions. Gut 2005;54(11):1638-1649. [34] St Pierre DH, Wang L, Taché Y. Ghrelin: a novel player in the gut-brain regulation of growth hormone and energy balance. News Physiol Sci 2003;18:242-246. [35] Van der Lely AJ, Tschöp M, Heiman ML, Ghigo E. Biological physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004;25(3):426-457. [36] Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin--a hormone with multiple functions. Front Neuroendocrinol 2004;25(1):27-68. [37] Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402(6762):656-660. [38] Hotta M, Ohwada R, Katakami H, Shibasaki T, Hizuka N, Takano K. Plasma levels of intact and degraded ghrelin and their responses to glucose infusion in anorexia nervosa. J Clin Endocrinol Metab 2004;89(11):5707-5712. [39] Wiedmer P, Nogueiras R, Broglio F, D'Alessio D, Tschöp MH. Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab 2007;3(10):705-712. [40] Tschöp M, Weyer C, Tataranni PA. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50(4):707-709. [41] Talukder MJ, Takeuchi T, Harada E. Receptor-mediated transport of lactoferrin into the cerebrospinal fluid via plasma in young calves. J Vet Med Sci 2003;65(9):957-964. [42] Baldwin GS, Bacic T, Chandler R, Grego B, Pedersen J, Simpson RJ, et al. Isolation of transferrin from porcine gastric mucosa: comparison with porcine serum transferrin. Comp Biochem Physiol B 1990;95(2):261-268. [43] Banks WA, Tschöp M, Robinson SM, Heiman ML. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 2002;302(2):822-827. [44] Gosk S, Vermehren C, Storm G, Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J Cereb Blood Flow Metab 2004;24(11):1193-1204. [45] Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002;54(4):561-587. [46] Pang Z, Lu W, Gao H, Hu K, Chen J, Zhang C, et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release 2008;128(2):120-127. [47] Ji B, Maeda J, Higuchi M, Inoue K, Akita H, Harashima H. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci 2006;78(8):851-855. [48] Kurosaki T, Kitahara T, Kawakami S, Higuchi Y, Yamaguchi A, Nakagawa H, et al. γ-Polyglutamic acidcoated vectors for effective and safe gene therapy. J Control Release 2010;142(3):404-410. [49] Liang HF, Yang TF, Huang CT, Chen MC, Sung HW. Preparation of nanoparticles composed of poly(γ-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells. J Control Release 2005;105(3):213-225. [50] Kuo YC, Yu HW. Transport of saquinavir across human brain-microvascular endothelial cells by poly(lactide-co-glycolide) nanoparticles with surface poly-(γ-glutamic acid). Int J Pharm 2011;416(1):365-375 [51] Kuo YC, Yu HW. Expression of ornithine decarboxylase during the transport of saquinavir across the blood-brain barrier using composite polymeric nanocarriers under an electromagnetic field. Colloids Surf B Biointerfaces 2011;88(2):627-634. [52] Discher DE, Eisenberg A. Polymer vesicles. Science 2002;297:967-973. [53] Discher D E, Ahmed F. Polymersomes. Annu Rev Biomed Eng 2006;8:323-341. [54] Bermudez H, Brannan AK, Hammer DA, Bates FS, Discher DE. Molecular weight dependence of polymersome membrane structure, elasticity, and stability. Macromolecules 2002;35(21):8203-8208. [55] Ahmed F, Discher DE. Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. J Control Release 2004;96(1):37-53. [56] Meng F, Engbers GHM, Feijen J. Biodegradable polymersomes as a basis for artificial cells: encapsulation, release and targeting. J Control Release 2005;101(1-3):187-198. [57] Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 2003;90(3):323-334. [58] Discher DE, Ortiz V, Srinivas G, Klein ML, Kim Y, Christian D, et al. Emerging applications of polymersomes in delivery: from molecular dynamics to shrinkage of tumors. Prog Polym Sci 2007;32(8-9):838-857. [59] Pang ZQ, Lu W, Gao H, Hu K, Chen J, Zhang C, et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release 2008;128(2):120-127. [60] Upadhyay KK, Bhatt AN, Mishra AK, Dwarakanath BS, Jain S, Schatz C, et al. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes. Biomaterials 2010;31(10):2882-2892. [61] Pang Z, Feng L, Hua R, Chen J, Gao H, Pan S, et al. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm 2010;7(6):1995-2005. [62] Gao HL, Pang ZQ, Fan L, Hu KL, Wu BX, Jiang XG. Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: in vitro and in vivo evaluations. Acta Pharmacol Sin 2010;31(2):237-243. [63] Nie T, Zhao Y, Xie ZW, Wu C. Micellar formation of poly(caprolactone-block- ethylene oxide-block-caprolactone) and its enzymatic biodegradation in aqueous sispersion. Macromolecules 2003;36(23):8825-8829. [64] Burchard W, Patterson GD. Light Scattering from Polymers. Berlin: Springer- Verlag;1983. [65] Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. J Control Release 2009;134(1):55-61. [66] Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 2001;46(1-3):247-279. [67] Schmauss C, Yaksh, TL. In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differencial association of mu, delta and kappa receptors with visceral, chemical and cutaneos thermal stimuli in the rat. J Pharmacol Exp Ther 1984;228(1):1-12. [68] Jensen TS, Yaksh TL. Comparison of antinociceptive action of morphine in the periaqueductal gray medial and paramedial medulla in rat. Brain Res 1986;363(1):99-113. [69] Elyad M, Davidson MD, Doursout MF, Peter S, Jacques E, Chelly MD. Antinociceptive and cardiovascular properties of esmolol following formalin injection in rats. Can J Anesth 2001;48(1):59-64. [70] Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C, Klein C, et al. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci 2002;15(8):1317-1326. [71] Afergan E, Epstein H, Dahan R, Koroukhov N, Rohekar K, Danenberg H. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Release 2008;132(2):84-90. [72] Moghimi S, Hunter A, Murray J. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;17:283-318. [73] Storm G, Belliot S, Daemen T, Lasic D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995;17:31-48. [74] Loging W, Lal A, Siu I, Loney T, Wikstrand C, Marra M. Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res 2000;10(9):1393-1402. [75] Lammers T, Kiessling F, Hennink W, Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm 2010;7(6):1899-1912. [76] Parveen S, Sahoo SK. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol 2011;670(2-3):372-383. [77] Parveen S, Mitra M, Krishnakumar S, Sahoo SK. Enhanced antiproliferative activity of carboplatin-loaded chitosan-alginate nanoparticles in a retinoblastoma cell line. Acta Biomater 2010;6(8):3120-3131. [78] Torchilin V. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4(2):145-160. [79] Gan CW, Feng SS. Transferrin-conjugated nanoparticles of poly(lactide)-D-a- Tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood–brain barrier. Biomaterials 2010;31(30):7748-7757. [80] Delhanty PJ, Sun Y, Visser JA, van Kerkwijk A, Huisman M, van Ijcken WF, Swagemakers S et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS ONE 2010;5:e11749 [81] Miegueu P, St Pierre D, Broglio F, Cianflone K. Effect of desacyl ghrelin, obestatin and related peptides on triglyceride storage, metabolism and GHSR signaling in 3T3-L1 adipocytes. J Cellular Biochem 2011;112:704–714 [82] Baragli A, Ghe C, Arnoletti E, Granata R, Ghigo E, Muccioli G.. Acylated and unacylated ghrelin attenuate isoproterenol-induced lipolysis in isolated rat visceral adipocytes through activation of phosphoinositide 3-kinase g and phosphodiesterase 3B. Biochimica et Biophysica Acta 201; 1811:386–396 [83] Granata R, Settanni F, Biancone L, Trovato L, Nano R, Bertuzzi F, et al. Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic b-cells and human islets: involvement of 30,50-cyclic adenosine monophosphate/protein kinase A, extracellular signalregulated kinase 1/2, and phosphatidyl inositol 3-kinase/Akt signaling. Endocrinol 2007;148:512–529 [84] Cederberg H, Rajala U, Koivisto VM, Jokelainen J, Surcel HM, Keinanen- Kiukaanniemi S, et al. Unacylated ghrelin is associated with changes in body composition and body fat distribution during long-term exercise intervention. Eur J Endocrinol 2011;165:243–248 [85] Gauna C, Delhanty PJ, van Aken MO, Janssen JA, Themmen AP, Hofland LJ et al. Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor. Mol Cell Endocrinol 2006;251:103–111 [86] Halem HA, Taylor JE, Dong JZ, Shen Y, Datta R, Abizaid Aet al. A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weightgain. Neuroendocrinol 2005;81:339–349 [87] Iacob G, Dinca EB. Current data and strategy in glioblastoma multiforme. J Med Life 2009;2:386-393. [88] Hegi ME, Diserens AC, Gorlia T, Hamou MF, De-Tribolet N, Weller M. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. [89] Donahue MJ, Blakeley JO, Zhou J, Pomper MG, Laterra J, Van-Zijl PC. Evaluation of human brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches. Magn Reson Med 2008;59:336-344. [90] Yan H, Wang J, Yi P, Lei H, Zhan C, Xie C. Imaging brain tumor by dendrimer- based optical/paramagnetic nanoprobe across the blood-brain barrier. Chem Commun (Camb) 2011;47:8130-8132. [91] Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discovery Today 2008;13:1099–1106. [92] Bredel M, Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncol 2002;3:397–406. [93] Eichler AF, Chung E. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 2011;8:344-356. [94] Lee J, Lund-Smith C. Glioma-induced remodeling of the neurovascular unit. Brain Research 2009;1288:125-134. [95] Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S, et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 2001;92:1936–1942. [96] Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007;24:1759–1771. [97] Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004;10: 3667–3677. [98] Du J, Lu WL, Ying X, Liu Y, Du P, Tian W, et al. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood−brain barrier and survival of brain tumor-bearing animals. Mol Pharmaceutics 2009;6:905–917. [99] Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharmaceutics 2008;5:496–504. [100] Lee JCM, Bermudez H, Discher BM, Sheehan MA, Won YY, Bates FS, et al. Preparation, stability, and in vitro performance of vesicles made with diblock copolymers. Biotechnol Bioeng 2001;73:135–145. [101] Ghoroghchian PP, Lin JJ, Brannan AK, Frail PR, Bates FS, Therien MJ, et al. Quantitative membrane loading of polymer vesicles. Soft Matter 2006;2: 973–980. [102] Lomas H, Canton I, MacNeil S, Du J, Armes SP, Ryan AJ, et al. Biomimetic pH sensitive polymersomes for efficient DNA encapsulation and delivery. Adv Mater 2007:19:4238–4243. [103] Discher BM, Won YY, Ege DS, Lee JCM, Bates FS, Discher DE, et al. Polymersomes: Tough Vesicles Made from Diblock Copolymers. Science 1999;284:1143–1146. [104] Won YY, Davis HT, Bates FS, Agamalian M, Wignall GD. Segment distribution of the micellar brushes of poly(ethyleneoxide) via small-angle neutron scattering. J Phys Chem B 2000;104:7134–7143. [105] Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. J Controlled Release 2003;90:323–334. [106] Chen YC, Chiang CF, Chen LF, Liao SC, Hsieh WY, Lin W-L. Polymersomes conjugated with des-octanoyl ghrelin for the delivery of therapeutic and imaging agents into brain tissues. Biomaterials 2014;35:2051-2065. [107] Kang C. Evaluation of folate-PAMAM for the delivery of antisense oligonucleotides to rat C6 glioma cells in vitro and in vivo. J Biomed Mater Res A 2010;93:585-594. [108] Wang J, Liu W, Tu Q, Wang J, Song N, Zhang Y, et al. Folate-decorated hybrid polymeric nanoparticles for chemically and physically combined paclitaxel loading and targeted delivery. Biomacromolecules 2011;12: 228-234. [109] Wang X, Duan X, Yang G, Zhang X, Deng L, Zheng H. Honokiol crosses BBB and BCSFB and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One 2011; 6: e18490. [110] Pardridge WM. Vector-mediated drug delivery to the brain. Adv Drug Deliv Rev 1999;36:299-321. [111] Lu W, Sun Q, Wan J, She Z, Jiang XG. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 2006;66:11878-11887. [112] Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 2011;13:e17. [113] Gao H, Pan S, Yang Z, Cao S, Chen C, Jiang X. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2peptide and EGFP-EGF1 protein. Biomaterials 2011;32:8669-8675. [114] Kuo YC, Chen HH. Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. J Drug Target 2010;18:447–456. [115] Callahan MK, Williams KA, Kivisakk P, Pearce D, Stins MF, Ransohoff RM. CXCR3 marks CD4t memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J Neuroimmunol 2004;153:150-157. [116] Pan H, Han L, Chen W, Yao M, Lu W. Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. J Controlled Release 2008;125:228–235. [117] Schoch G, Seeger H, Bogousslavsky J, Tolnay M, Janzer RC, Aguzzi A, et al. Analysis of prion strains by PrPSc profiling in sporadic Creutzfeldt-Jakob disease. PLoS Med 2006;3:e14. [118] Discher BM, Won YY, Ege DS, Lee JC, Bates FS, Discher DE, et al. Polymersomes: tough vesicles made from diblock copolymers. Science 1999; 284:1143–1146. [119] Discher BM, Bermudez H, Hammer DA, Discher DE. Cross-linked polymersome membranes: vesicles with broadly adjustable properties. J Phys Chem B 2002;106:2848–2854. [120] Levine DH, Ghoroghchian PP, Freudenberg J, Zhang G, Therien MJ, Greeneet MI, et al. Polymersomes: a new multi-functional tool for cancer diagnosis and therapy. Methods 2008;46:25–32. [121] Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-782. [122] Mackay JA, Deen DF, Szoka FC. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 2005;1035:139-153. [123] Nie T, Zhao Y, Xie ZW, Wu C. Micellar formation of poly(caprolactone-block- ethylene oxide-block- caprolactone) and its enzymatic biodegradation in aqueous sispersion. Macromolecules 2003;36:8825-8829. [124] Burchard W. Static and dynamic light scattering from branched polymers and biopolymers. AdV Polym Sci 1983;48: 1-124. [125] Dong H, Dube N, Shu JY, Seo JW, Mahakian LM, Ferrara KW, et al. Long-Circulating 15 nm Micelles Based on Amphiphilic 3-Helix Peptide-PEG Conjugates. ACS Nano 2012;6:5320–5329. [126] Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. J Control Release 2009;134:55-61. [127] Hau P, Fabel K. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004;100(6):1199–1207. [128] Sakai N, Kondo H. Postoperative treatment for malignant intracranial tumors – especially concerning intermittent intra-carotid administration of Adriamycin. No Shinkei Geka 1984;12(3 Suppl):237–243. [129] Merker PC, Lewis MR, Walker MD, Richardson Jr EP. Neurotoxicity of doxorubicin (doxorubicin) perfused through the cerebrospinal fluid spaces of the rhesus monkey. Toxicol Appl Pharmacol1978;44(1):191-205. [130] Neuwelt EA, Pagel M, Barnett P, Glassberg M, Frenkel EP. Pharmacology and toxicity of intracarotid doxorubicin administration following osmotic blood-brain barrier modification. Cancer Res 1981;41(11 Pt 1):4466–4470. [131] Ohnishi T, Tamai I, Sakanaka K, Sakata A, Yamashima T, Yamashita J, Tsuji A. In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. Biochem Pharmacol 1995;49(10):1541–1544. [132] Khil MS, Kolozsvary A, Apple M, Kim JH. Increased tumor cures using combined radiosurgery and BCNU in the treatment of 9l glioma in the rat brain, Int J Radiat Oncol Biol Phys 2000;47(2): 511-516. [133] Vykhodtseva N, McDannold N, Hynynen K. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics 2008;48(4):279-296. [134] Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 2007;121(4):901-907. [135] Wang F, Cheng Y, Mei J, Song Y, Yang YQ, Liu Y. Focused ultrasound microbubble destruction-mediated changes in blood-brain barrier permeability assessed by contrast-enhanced magnetic resonance imaging. J Ultrasound Med 2009;28(11):1501-1509. [136] Adair JC, Baldwin N, Kornfeld M, Rosenberg GA. Radiation-induced blood brain barrier damage in astrocytoma: relation to elevated gelatinase B and urokinase. J Neurooncol 1999;44(3):283-289. [137] Kang C, Yuan X, Zhong Y, Pu P, Guo Y, Albadany A, et al. Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D, L-lactic acid) nanoparticles. Technol Cancer Res Treat 2009;8(1):61-70. [138] Vogelhuber W, Spruss T, Bernhardt G, Buschauer A, Göpferich A. Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts. Int J Pharm 2002;238 (1-2):111-121. [139] Xu X, Chen X, Xu X, Lu T, Wang X, Yang L. BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells. J Control Release 2006;114(3):307-316. [140] Gao JQ, Lv Q, Li LM, Tang XJ, Li FZ, Hu YL, Han M. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. Biomaterials 2013;34 (22):5628-5639. [141] Kim GY, Tyler BM, Tupper MM, Karp JM, Langer RS, Brem H. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank mode. J Control Release 2007;123(2):172-178. [142] McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res 2012;72(14): 3652-3663. [143] Fan CH, Ting CY, Liu HL, Huang CY, Hsieh HY, Yen TC, et al. Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment. Biomaterials 2013;34(8):2142-2155. [144] Ting CY, Fan CH, Liu HL, Huang CY, Hsieh HY, Yen TC, wt al. Concurrent blood–brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment. Biomaterials 2012;33(2):704-712. [145] Gao Z, Kennedy AM, Christensen DA, Rapoport NY. Drug-loaded nano/ microbubbles for combining ultrasonography and targeted chemotherapy. Ultrasonics 2008;48(4):260–270. [146] Tinkov S, Bekeredjian R, Winter G, Coester C. Microbubbles as ultrasound triggered drug carriers. J Pharm Sci 2009; 98(6):1935-1961. [147] Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene Delivery. Adv Drug Deliv Rev 2008;60:1153–1166. [148] Willmann JK, Cheng Z, Davis C, Lutz AM, Schipper ML, Nielsen CH, Gambhir SS. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology 2008;249(1):212–219. [149] Rapoport N, Nam KH, Gupta R, Gao Z, Mohan P, Payne A, Todd N, Liu X, Kim T, Shea J, Scaife C, Parker DL, Jeong EK, Kennedy AM. Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions. J Control Release 2011;153(1):4-15. [150] Cochran MC, Eisenbrey J, Ouma RO, Soulen M, Wheatley MA. Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery. Int J Pharm 2011;414(1-2):161–170. [151] Geers B, Lentacker I, Sanders NN, Demeester J, Meairs S, De Smedt self-assembled liposome-loaded microbubbles: the missing link for safe and efficient ultrasound triggered drug-delivery. J Control Release 2011;152(2):249–256. [152] Park EJ, Zhang YZ, Vykhodtseva N, McDannold N. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. Journal of Controlled Release 2012;163(3):277-284. [153] Chen YC, Chiang CF, Chen LF, Liang PC, Hsieh WY, Lin WL. Polymersomes conjugated with des-octanoyl ghrelin and folate as a BBB-penetrating cancer cell-targeting delivery system. Biomaterials 2014;35(13):4066-4081.. [154] Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003;100:8621–8623. [155] Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 2006;66(13):6714–6721. [156] Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011;6(12):815-823. [157] Dohgu S, Yamauchi A, Takata F, Naito M, Tsuruo T, Higuchi S, et al. Transforming growth factor-h1 upregulates the tight junction and P-glycoprotein of brain microvascular endothelial cells. Cell Mol Neurobiol 2004;24(3):491–497. [158] Hayashi K, Nakao S, Nakaoke R, Nakagawa S, Kitagawa N, Niwa M. Effects of hypoxia on endothelial/pericytic co-culture model of the blood–brain barrier. Regul Pept 2004;123(1-3):77– 83. [159] Dohgu S, Takata F, Yamauchi A, Nakagawa S, Egawa T, Naito M, et al. Brain pericytes contribute to the induction and up-regulation of blood–brain barrier functions through transforming growth factor-h production. Brain Res 2005;1038(2):208-15. [160] Weng JC, Wu SK, Lin WL, Tseng WY. Detecting blood–brain barrier disruption within minimal hemorrhage following transcranial focused ultrasound: a correlation study with contrast-enhanced MRI. Magnetic Resonance in Medicine 2011;65(3):802–811. [161] Schoch G, Seeger H, Bogousslavsky J, Tolnay M, Janzer RC, Aguzzi A, et al. Analysis of prion strains by PrPSc profiling in sporadic Creutzfeldt-Jakob disease. PLoS Med 2006;3(2):e14. [162] Sheikov N, McDannold N, Vykhodtseva N, Jolesz F, Hynynen K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol 2004;30(7):979–989. [163] Tachibana K, Uchida T, Ogawa K, Yamashita N, Tamura K. Induction of cell-membrane porosity by ultrasound. Lancet 1999;353(9162):1409. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4044 | - |
dc.description.abstract | 血腦屏障的緊密連接構造與排外運輸系統大幅限制了95%中樞神經疾病的藥物/基因。為了促進大腦專一性的藥物傳輸,在本研究的第一部分,我們開發一種標靶型載體系統,此系統包含鍵結去辛醯化生長素釋質的poly(carboxyl ethylene glycol-g-glutamate)-co-poly(distearin-g-glutamate) (CPEGGM-PDSGM)之高分子囊胞。根據報導指出去辛醯化生長素釋質能單向通過血腦屏障 (血液通往大腦的方向)。然而,沒有任何的報導去確認去辛醯化生長素釋質鍵結在藥物載體系統上是否能藉由去辛醯化生長素釋質結合位置的介導內吞作用來標靶血腦屏障。為了定性和定量研究這種載體的特性,coumarin 6、 Cy5.5和met-enkephalin各自被包覆於高分子囊泡中。研究結果顯示當共同培養於血腦屏障細胞時,去辛醯化生長素釋質鍵結後的高分子囊胞(GPs)的細胞攝取,顯著的比未鍵結的高分子囊胞高。除此之外,在動物實驗的研究中也指出GPs對腦具有較高的選擇性,能增加在腦中的藥物累積量並減少在肝臟與脾臟的藥物累積。在熱板試驗與福馬林研究顯示,以靜脈注射包覆有met-enkephalin的GPs對於疼痛反應具有比較顯著的抑制效果。由整體結果證實,GPs具有潛力能發展通過血腦屏障並治療中樞神經性疾病的標的傳輸系統。
腦腫瘤在臨床醫學治療上一直是一個很大的挑戰,起因於無法讓足夠的藥物通過血腦屏障與藥物進入腫瘤具有低滲透性。為了有效的治療腦腫瘤與降低正常組織的副作用,因此,在研究的第二部分我們製備去辛醯化生長素釋質與葉酸鍵結的doxorubicin的高分子囊胞(GFP-D),去促進高分子囊胞通過血腦屏障並標的腦腫瘤。尺寸測量結果顯示,此這種穿透血腦屏障與癌細胞標的型高分子囊胞的顆粒大小為約85 nm。在體外用血腦屏障細胞模型和C6膠質瘤細胞實驗結果指出,GFP-D具有較強的穿透與標靶特性的藥物傳遞。在C6細胞生存能力測試中,GFP-D比未改質的doxorubicin高分子囊泡(PD)具有較顯著的抑制效果。在體內抗腫瘤實驗中顯示,GFP-D比施予doxorubicin (Dox), doxorubicin的微脂體(L-D), P-D, 或是單一配體鍵結的高分子囊胞在抗神經膠質瘤的效果與植入腦瘤的小鼠總體存活率方面都較高。此外, Cy5.5也被包覆用來評估此種穿透性標靶傳輸系統的遞送特性。整體的實驗結果指出,此種穿透性標靶傳輸系統GFP-D在腦腫瘤的治療上是一種具有高潛力的奈米載體。 在本研究的第三部分,我們開發去辛醯化生長素釋質鍵結的微氣泡(GMB)並包覆TGFβ1抑制劑 (LY364947) (GMBL),並藉由結合超音波(US)的方式誘導血腦屏障/血瘤屏障(BBB / BTB)的瓦解。在體外穩定性研究中顯示,GMB的穩定性能維持一個月以上。在體內研究中也指出,施予folate鍵結的doxorubicin 高分子囊胞 (FPD) 並經由 GMBL/US 處理(FPD+GMBL/US),能達到最好的抑制神經膠質瘤的效果並能改善植入腦瘤的小鼠總體存活率。當結合聚焦是超音波時,GMBL能促進血腦屏障/血瘤屏障的瓦解並同時釋放出LY364947,LY364947能降低腦腫瘤內皮的週細胞覆蓋,會增強FPD的累積和抗腫瘤活性。整體的實驗結果指出,FPD+GMBL/US這種非侵入性標靶傳輸方式,能促進奈米藥物進入到腦腫瘤中,並達到治療的效果與降低正常腦組織的藥物毒性,此種治療方式於CNS疾病治療上是具有很大的潛力。 | zh_TW |
dc.description.abstract | The effective protection of the blood-brain barrier (BBB) from tight junctions and efflux transport systems ultimately results in the limited entry of 95% of drug/gene candidates, which are potentially beneficial for central nervous system (CNS) diseases. In order to enhance the brain-specific delivery, in present part of this study we developed a targeting nano drug carrier system, which consists of poly(carboxyl ethylene glycol-g-glutamate)-co-poly(distearin-g-glutamate) (CPEGGM-PDSGM) polymersomes with the conjugation of des-octanoyl ghrelin. Des-octanoyl ghrelin across the BBB was reported to be unidirectional (blood-to-brain direction). However, there is no report about the conjugation of des-octanoyl ghrelin to a drug carrier system to confer the BBB targeting property through des-octanoyl ghrelin binding sites mediated endocytosis. To qualitatively and quantitatively investigate this carrier’s properties, coumarin 6, Cy5.5 and met-enkephalin were individually encapsulated in these polymersomes. The experimental results showed that the cellular uptake was significantly higher for des-octanoyl ghrelin-conjugated polymersomes (GPs) than unconjugated polymersomes when co-incubated with the BBB cells. In addition, an enhanced accumulation in brain together with a reduced accumulation in liver and spleen was observed in animal study, indicating better brain selectivity for the GPs. In a hot-plate test and formalin test, a significant inhibition of nociceptive response could be achieved for an intravenous injection of GPs encapsulated with metenkephalin. The overall results demonstrated that GPs own a great potential for targeting delivery of drug across the BBB to treat CNS diseases.
Chemotherapy for brain cancer tumors remains a big challenge for clinical medicine due to the inability to transport sufficient drug across the BBB and the poor penetration of drug into the tumors. To effectively treat brain tumors and reduce side effects on normal tissues, both des-octanoyl ghrelin and folate conjugated with polymersomal doxorubicin (GFP-D) was developed in second part of this study to help transport across the BBB and target the tumor as well. The size measurements revealed that this BBB-penetrating cancer cell-targeting GFP-D was about 85 nm. In-vitro experiments with a BBB model and C6 glioma cells demonstrated that GFP-D owned a robust penetrating-targeting function for drug delivery. In C6 cell viability tests, GFP-D exhibited an inhibitory effect significantly different from the unmodified polymersomal doxorubicin (P-D). In-vivo antitumor experiments showed that GFP-D performed a much better anti-glioma effect and presented a significant improvement in the overall survival of the tumor-bearing mice as compared to the treatments with free doxorubicin (Dox), liposomal doxorubicin (L-D), P-D, or single ligand conjugated P-D. In addition, Cy5.5 was used as a probe to investigate the delivery property of this penetrating-targeting delivery system. The overall experimental results indicate that this BBB-penetrating cancer cell-targeting GFP is a highly potential nanocarrier for the treatment of brain tumors. In third part of this study, we developed the des-octanoyl ghrelin conjugated microbubbles (GMB) loaded with TGFβ1 inhibitor (LY364947) (GMBL) to induce BBB/BTB disruption for ultrasound (US) sonication with GMBL. The in-vitro stability study showed that GMB was pretty stable over one month. The in-vivo study showed that the combination of folate-conjugated polymersomal doxorubicin (FPD) and GMBL/US (FPD+GMBL/US) achieved the best anti-glioma effect and significant improvement in the overall survival time for brain tumor-bearing mice. When combined with focused US, GMBL facilitated local BBB/BTB disruption and simultaneously released LY364947 to decrease the pericyte coverage of the endothelium at the targeted brain tumor sites, resulting in enhanced accumulation and antitumor activity of FPD. The overall results indicate that GMBL/US owns a great potential for non-invasive targeting delivery of nanomedicine across the BBB to treat central nervous system (CNS) diseases. | en |
dc.description.provenance | Made available in DSpace on 2021-05-13T08:41:06Z (GMT). No. of bitstreams: 1 ntu-105-D02548001-1.pdf: 5414307 bytes, checksum: c51807ebd10358bb720eda1886042771 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | Contents
Acknowledgements……………………………………………………………………... I 中文摘要………………………………………………………………………………II Abstract………………………………………………………………………………...IV Contents………………………………………………………………………………VII List of Figures……………………………………………………………………….XIV List of Tables……………………………………………………………………….XXII Chapter 1. Background…………………………………………………………………..1 1.1. Central nervous system disease……………………………………………….1 1.2. Blood-brain barrier (BBB)………………………………………....................2 1.3. BBB transport systems………………………………………………………..3 1.4. Strategies for drug delivery to the brain across the BBB……………………..5 1.4.1. Physiological approaches……………………………………………..5 1.4.2. Disruption of the BBB………………………………………………..6 1.5. Major problems and specific aims…………………………………………….7 Chapter 2. Polymersomes Conjugated with Des-octanoyl Ghrelin for the Delivery of Therapeutic and Imaging Agents into Brain Tissues………….....................12 2.1. Introduction……………………………………………………......................12 2.2. Materials, methods and experiments………………………………………...16 2.2.1. Materials………………………………………………………………16 2.2.2. Synthesis and characterization of polymer……………………………17 2.2.2.1. Synthesis and characterization of poly(glutamic succinimidyl ester)-co-poly(distearin-g-glutamate) (PGNHS-PDSGM)……..17 2.2.2.2. Synthesis and characterization of the poly(carboxyl ethylene glycol-g-glutamate)-co-poly(distearin-g-glutamate) (CPEGGM-PDSGM) copolymer…………………………….…18 2.2.2.3. Synthesis and characterization of poly(methyl ethylene glycol-g-glutamate)-co-poly(distearin-g-glutamate) (mPEGGM-PDSGM) copolymer………………………………19 2.2.2.4.Synthesis and characterization of des-octanoyl ghrelin -poly(ethyleneglycol-g-glutamate)-co-poly(distearin-g-glutamate) (des-octanoyl ghrelin- PEGGM-PDSGM) copolymer…………20 2.2.3. Preparation of Polymersomes………………………………………….21 2.2.4. Preparation of polymersomes encapsulated with met-enkephalin…….21 2.2.5. Preparation of polymersomes encapsulated with coumarin 6 or Cy5.5 ………………………………………………………………………....22 2.2.6. Particle size and surface morphology of polymersomes………………23 2.2.7. Encapsulation of met-enkephalin, coumarin 6 and Cy5.5 for polymersomes.........................................................................................24 2.2.8. BBB cell culture………………………………………………………..25 2.2.9. Transport across the BBB in the transwell system……………………..26 2.2.10. Qualitative study of the uptake of polymersomes by the BBB cells….27 2.2.11. Quantitative study of the uptake of polymersomes by the BBB cells……………………………………………………………………28 2.2.12. In-vivo experiments…………………………………………………...29 2.2.13. Hot-plate test…………………………………………………………..29 2.2.14. Formalin test…………………………………………………..............30 2.2.15. Distribution of coumarin 6 in the brain…………………….................31 2.2.16. Pharmacokinetics of polymersomes…………………………………..32 2.2.17. In-vivo biodistribution and fluorescence image of polymersomes……34 2.3. Results and discussion………………………………………….....................35 2.3.1. Characterization of copolymer composition………………………….35 2.3.2. Characterization of polymersomal met-enkephalin (PE), polymersomal coumarin 6 (PC), polymersomal Cy5.5 (P5), Des-octanoyl ghrelin-conjugated polymersomal met-enkephalin (GPE), Des-octanoyl ghrelin-conjugated polymersomal coumarin 6 (GPC), and Des-octanoyl ghrelin-conjugated polymersomal Cy5.5 (GP5)………………………36 2.3.3. Transport across the BBB in the transwell system…………………....38 2.3.4. Qualitative study of the uptake of polymersomes for the BBB cells……………………………………………………………………40 2.3.5. Quantitative study of the uptake of polymersomes for the BBB cells…....................................................................................................41 2.3.6. Hot-plate test…………………………………………………………..42 2.3.7. Formalin test…………………………………………………………..43 2.3.8. Distribution of coumarin 6 in the brain……………………………….44 2.3.9. Pharmacokinetic study……………………………………………….46 2.3.10. In-vivo biodistribution and fluorescence image of polymersomes…48 2.4. Conclusion…………………………………………………………………..51 Chapter 3. Polymersomes Conjugated with Des-octanoyl Ghrelin and Folate as a BBB-penetrating Cancer Cell-targeting Delivery System for Brain Tumor Ttreatments……………………………………………………………………69 3.1. Introduction…………………………………………………………………..69 3.2. Materials, methods an experiments……………………………………….....73 3.2.1. Materials………………………………………………………………73 3.2.2. Synthesis and characterization of polymer…………………………....73 3.2.2.1. Synthesis and characterization of poly(tert-butyl hydrazine carboxylate ethylene glycol-g-glutamate)-co-poly(distearin-g- glutamate) (BPEGGM-PDSGM) copolymer…………………..73 3.2.2.2. Folate-poly(ethylene glycol-g-glutamate)-co-poly(distearin-g- glutamate) (folate-PEGGM-PDSGM) copolymer……………...74 3.2.3. Preparation of different types of polymersomes encapsulated with doxorubicin (polymersomal doxorubicin (P-D), folate conjugated polymersomal doxorubicin (FP-D), des-octanoyl ghrelin conjugated polymersomal doxorubicin (GP-D), and des-octanoyl ghrelin and folate conjugated polymersomal doxorubicin (GFP-D))…………………….75 3.2.4. Preparation of different polymersomes encapsulated with Cy5.5 (polymersomal Cy5.5 (P-5), folate conjugated polymersomal Cy5.5 (FP-5), des-octanoyl ghrelin conjugated polymersomal Cy5.5 (GP-5), and des-octanoyl ghrelin and folate conjugated polymersomal Cy5.5 (GFP-5))……………………………………………………………….76 3.2.5. Characterization of various types of polymersomal Dox……………..77 3.2.6. Cell culture……………………………………………………………79 3.2.7. Uptake of various types of polymersomal Dox by the C6 glioma cells in the in-vitro BBB model……………………………………………….80 3.2.8. Cytotoxicity of various types of polymersomal Dox against C6 glioma cells in the in-vitro BBB model……………………………………….81 3.2.9. In-vivo experiments…………………………………………………...82 3.2.9.1. Pharmacokinetic study and deposition of various types of polymersomal Dox in brain tissues…………………………….82 3.2.9.2. Qualitative study of various types of polymersomal Dox in brain tumors…………………………………………………………84 3.2.9.3. In-vivo anti-tumor experiments………………………………..84 3.2.9.4. Apoptosis detection for brain tumor cells and normal brain tissue…………………………………………………………..85 3.2.9.5. Biodistribution of polymersomes……………………………...86 3.3. Results and discussion………………………………………………………..87 3.3.1. Characterization of copolymer composition…………………………..87 3.3.2. Characterization of various types of polymersomal Dox……………..87 3.3.3. Uptake of various types of polymersomal Dox for in-vitro C6 glioma cells……………………………………………………………………91 3.3.4. Cytotoxicity of various types of polymersomal Dox against C6 glioma cells in the in-vitro BBB model……………………………………….92 3.3.5. Pharmacokinetic study………………………………………………..93 3.3.6. Dox deposition in brain/tumor tissues………………………………...94 3.3.7. In-vivo anti-glioma effect……………………………………………..96 3.3.8. Apoptosis detection of brain tumor cells and normal brain tissue……98 3.3.9. Biodistribution of polymersomes……………………………………..99 3.4. Conclusion…………………………………………………………………100 Chapter 4. Targeting Microbubbles-carrying TGFβ1 Inhibitor Combined with Ultrasound Sonication Induce BBB/BTB Disruption to Enhance Nanomedicine Treatment for Brain Tumors……………………………...118 4.1. Introduction…………………………………………………………………119 4.2. Materials, methods and experiments……………………………………….122 4.2.1. Materials……………………………………………………………..122 4.2.2. Methods……………………………………………………………...122 4.2.2.1. Preparation of des-octanoyl ghrelin- conjugated microbubbles (GMB) and GMB-carrying LY364947 (GMBL) and microbubbles (MB)…………………………………………...122 4.2.2.2. Physical properties and stability of microbubbles…………....123 4.2.2.3. In-vivo animal experiments…………………………………..124 4.2.2.4. Focused ultrasound (FUS) for in-vivo animal experiments….124 4.2.2.5. In-vivo stability of microbubbles…………………………….125 4.2.2.6. Drug deposition in brain tissues……………………………...125 4.2.2.7. In-vivo anti-tumor experiment……………………………......127 4.2.2.8. Apoptosis detection for brain tumor cells…………………….128 4.2.2.9. Statistical analysis method…………………………………..128 4.3. Results and discussions………………………………………………….….129 4.3.1. Physical properties and stability of microbubbles…………………...129 4.3.2. In-vivo stability of microbubbles……………………………………130 4.3.3. Deposition of Dox in brain tissues…………………………………..131 4.3.4. In-vivo anti-glioma effect……………………………………………134 4.4. Conclusion…………………………………………………………………..136 Chapter 5. Summary and Future Work…………………………………146 References…………………………………………………………………………….148 | |
dc.language.iso | en | |
dc.title | 研發應用於腦疾病治療之標靶型奈米藥物傳輸系統及超音波微氣泡 | zh_TW |
dc.title | Development of Targeting Nano Drug Delivery Systems and Ultrasound Microbubbles for Brain Disease Treatment | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-1 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 謝文元 | |
dc.contributor.oralexamcommittee | 許明照,陳三元,符文美,郭律廷,謝松蒼 | |
dc.subject.keyword | 高分子囊胞,微氣泡,TGFβ1抑制劑,葉酸,血腦/血瘤屏障(BBB/ BTB),標靶傳輸,超音波, | zh_TW |
dc.subject.keyword | polymersomes,microbubbles,TGFβ1 inhibitor,folate,blood-brain/blood-tumor barrier (BBB/BTB),targeted delivery,ultrasound, | en |
dc.relation.page | 166 | |
dc.identifier.doi | 10.6342/NTU201603631 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2016-10-03 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf | 5.29 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。